Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04108195 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma

StatusActive, Not Recruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

The 50 most recent of 78 record versions are accounted for below. See every version on ClinicalTrials.gov ↗

  1. Lead sponsor: Janssen Research & Development, LLC to Janssen Research & Development, LLC Completion pushed from Apr 7, 2027 to Dec 31, 2027 · Eligibility criteria expanded, about 10 words Show 2 more changesShow less
    • Completion pushed from Apr 7, 2027 to Dec 31, 2027
    • Eligibility criteria expanded, about 10 words
  2. 10 versions Re-verified since Nov 6, 2025, no change to tracked fieldsv68-v77
  3. Primary completion date: Aug 22, 2025 to Apr 7, 2027v67
  4. 6 versions Re-verified since Feb 27, 2025, no change to tracked fieldsv61-v66
  5. Completion date: Aug 22, 2025 to Apr 7, 2027v60
Show 31 earlier versionsHide 31 earlier versions
  1. Re-verified, no change to tracked fieldsv59
  2. Study sites revised (24)v58 See this version in full on ClinicalTrials.gov ↗
  3. Re-verified, no change to tracked fieldsv57
  4. Primary completion date: Sep 9, 2024 to Aug 22, 2025 Study description expanded, about 58 words · Study sites revised (24)v56 Show 2 more changesShow less
    • Study description expanded, about 58 words
    • Study sites revised (24)

    See this version in full on ClinicalTrials.gov ↗

  5. 2 versions Re-verified since Aug 13, 2024, no change to tracked fieldsv54-v55
  6. Study sites: 23 to 24v53
  7. Study sites revised (23)v52 See this version in full on ClinicalTrials.gov ↗
  8. Study sites: 22 to 23v51
  9. Enrollment target: 289 to 290v50
  10. Completion date: Sep 9, 2024 to Aug 22, 2025v49
  11. Re-verified, no change to tracked fieldsv48
  12. Enrollment target: 290 to 289v47
  13. Study sites revised (22)v46 See this version in full on ClinicalTrials.gov ↗
  14. Enrollment target: 291 to 290 Study sites revised (22)v45 Show 1 more changeShow less
    • Study sites revised (22)

    See this version in full on ClinicalTrials.gov ↗

  15. Study sites revised (22)v44 See this version in full on ClinicalTrials.gov ↗
  16. Enrollment target: 293 to 291v43
  17. Enrollment target: 294 to 293v42
  18. 2 versions Re-verified since Jul 19, 2023, no change to tracked fieldsv40-v41
  19. Site details revised at 1 of 22 sitesv39
  20. Enrollment target: 295 to 294v38
  21. Study Status, Study Description, Arms and Interventions, Eligibilityv37
  22. Study sites revised (22)v36 See this version in full on ClinicalTrials.gov ↗
  23. Enrollment target: 296 to 295v35
  24. Study sites revised (22)v34 See this version in full on ClinicalTrials.gov ↗
  25. Re-verified, no change to tracked fieldsv33
  26. Trial status: Recruiting to Active, Not Recruiting Enrollment target: estimated 290 to confirmed 296 · Study sites: 25 to 22v32 Show 2 more changesShow less
    • Enrollment target: estimated 290 to confirmed 296
    • Study sites: 25 to 22
  27. Enrollment target: 295 to 290v31
  28. 2 versions Re-verified since Sep 8, 2022, no change to tracked fieldsv29-v30
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to identify recommended Phase 2 doses (RP2Ds) for each treatment combination (between daratumumab plus talquetamab and teclistamab plus daratumumab with or without pomalidomide) and to characterize the safety of each RP2D for selected treatment combinations.
Trial Details
NCT Number NCT04108195
Lead Sponsor Janssen Research & Development, LLC
Conditions Multiple Myeloma
Enrollment 290 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov